POLYDEX PHARMACEUTICALS LIMITED POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY DISCLOSURE REPORT
OCTOBER 31, 2022
UNAUDITED
POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2022
UNAUDITED
INDEX
ITEM I | Name of Issuer | Page | 3 |
ITEM II | Share Structure | Page | 3 |
ITEM III | Consolidated Financial Statements | ||
Interim Financial Statements | Page | 4-9 | |
Notes to Interim Financial Statements | Page | 10-17 | |
ITEM IV | Management Discussion and Analysis | Page | 18-26 |
ITEM V | Legal Proceedings | Page | 27 |
ITEM VI | Defaults Upon Senior Securities | Page | 27 |
ITEM VII | Other Information | Page | 27 |
ITEM VIII | Exhibits | Page | 27 |
ITEM IX | Certifications | Page | 28-29 |
2
POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2022
UNAUDITED
ITEM I NAME OF ISSUER
Polydex Pharmaceuticals Limited
421 Comstock Road
Toronto, Ontario, Canada
M1L 2H5
Tel: (416) 755-2231
Fax: (416) 755-0334
Web: www.polydex.com
ITEM II SHARES OUTSTANDING
Preferred Stock - Class A
(i) | Period end date | October 31, 2022 |
(ii) | Authorized | 100,000 shares at $0.10 each |
(iii) | Issued and outstanding | None |
- Freely tradable shares (public
float)None
- Number of shareholders of
recordNone
Preferred Stock - Class B
(i) | Period end date | October 31, 2022 |
(ii) | Authorized | 899,400 shares at $0.0167 each |
(iii) | Issued and outstanding | 899,400 shares |
- Freely tradable shares (public
float)None
- Number of shareholders of
record1
Common Stock
(i) | Period end date | October 31, 2022 |
(ii) | Authorized | 10,000,000 shares |
(iii) | Issued and outstanding | 3,432,478 shares |
(iv) | Freely tradable shares (public | |
float) | 2,561,166 |
- Number of shareholders of
record206
3
POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2022
UNAUDITED
ITEM III INTERIM FINANCIAL STATEMENTS
CONSOLIDATED FINANCIAL STATEMENTS | |
(UNAUDITED) | |
TABLE OF CONTENTS | |
Consolidated Balance Sheets | |
October 31, 2022 and January 31, 2022 (Unaudited) | 5-6 |
Consolidated Statements of Operations and Comprehensive Income | |
Three and nine months ended October 31, 2022 and 2021 (Unaudited) | 7 |
Consolidated Statements of Shareholders' Equity | |
Nine months ended October 31, 2022 and 2021 (Unaudited) | 8 |
Consolidated Statements of Cash Flows | |
Nine months ended October 31, 2022 and 2021(Unaudited) | 9 |
Notes to Consolidated Financial Statements (Unaudited) | 10-17 |
4
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Polydex Pharmaceuticals Limited published this content on 30 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 December 2022 08:15:03 UTC.
